Translating Next-Generation Science Into Transformative Gene TherapiesLearn About Our Programs

Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Our diversity – whether gender, ethnicity, sexual …

Programs Encoded is building an internally developed pipeline of best- and potentially first-in-class therapies focused on neurological disorders.

Ever wondered what it takes to make a gene therapy? Join us on a virtual lab tour at Encoded’s headquarters in South San Francisco. Meet a few of our talented scientists ready to explain …

Encoded offers competitive pay, an equity program and benefits. We provide the support that team members need at work to succeed, and we give back the benefits and perks to maintain …

Encoded carefully designs clinical studies to assess safety and efficacy of its investigational gene therapies for the treatment of neurological disorders. People considering enrolling their child in …

Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy Society …

Encoded will be providing additional updates on its research pipeline, which is focused on both rare genetic and common disease programs, in addition to clinical progress with ETX101 for …

Contact Directory Patients Community and Clinical Trials [email protected] Healthcare Providers [email protected] Media [email protected] …

Encoded is developing ETX101, a potential one-time, disease-modifying gene regulation therapy for SCN1A+ Dravet syndrome. ETX101, Encoded’s lead program, is specifically designed to …